doi: 10.1016/j.ddtec.2018.10.001
The JAMA article mentioned above recognizes that during such situations the anesthesiologist and surgeon must take special precautions to avoid aspiration
For example, individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use GLP-1 medications
Semaglutide (STEP trials) In the landmark STEP 1 trial, participants on semaglutide 2.4 mg weekly lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% for placebo
Pair With Our Signature Programs Maximize your results by combining AOD-9604 with: Anti-inflammatory diet plans Cortisol-lowering stress protocols Advanced supplements for gut & metabolism Microbiome testing for personalized fat-loss plans Ready to Cut Fat, Sculpt Your Body, and Feel Amazing
Expanding options for optimizing type 2 diabetes treatment As the treatment landscape for type 2 diabetes continues to evolve, the findings from the SURPASS-SWITCH trial offer timely insight for clinicians managing patients who are not achieving glycemic or weight-related goals with their current GLP-1 receptor agonist regimen
